These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 12547710)

  • 1. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.
    Giordano TJ; Thomas DG; Kuick R; Lizyness M; Misek DE; Smith AL; Sanders D; Aljundi RT; Gauger PG; Thompson NW; Taylor JM; Hanash SM
    Am J Pathol; 2003 Feb; 162(2):521-31. PubMed ID: 12547710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.
    Giordano TJ; Kuick R; Else T; Gauger PG; Vinco M; Bauersfeld J; Sanders D; Thomas DG; Doherty G; Hammer G
    Clin Cancer Res; 2009 Jan; 15(2):668-76. PubMed ID: 19147773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
    Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
    Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.
    Slater EP; Diehl SM; Langer P; Samans B; Ramaswamy A; Zielke A; Bartsch DK
    Eur J Endocrinol; 2006 Apr; 154(4):587-98. PubMed ID: 16556722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors.
    Tacon LJ; Soon PS; Gill AJ; Chou AS; Clarkson A; Botling J; Stalberg PL; Skogseid BM; Robinson BG; Sidhu SB; Clifton-Bligh RJ
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4591-9. PubMed ID: 19820023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discerning malignancy in adrenocortical tumors: are molecular markers useful?
    Wachenfeld C; Beuschlein F; Zwermann O; Mora P; Fassnacht M; Allolio B; Reincke M
    Eur J Endocrinol; 2001 Sep; 145(3):335-41. PubMed ID: 11517015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional profiling enables molecular classification of adrenocortical tumours.
    Laurell C; Velázquez-Fernández D; Lindsten K; Juhlin C; Enberg U; Geli J; Höög A; Kjellman M; Lundeberg J; Hamberger B; Larsson C; Nilsson P; Bäckdahl M
    Eur J Endocrinol; 2009 Jul; 161(1):141-52. PubMed ID: 19411298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
    Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
    J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
    Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression patterns associated with hyperfunctioning and non-hyperfunctioning phenotypes in adrenocortical adenomas.
    Velázquez-Fernández D; Caramuta S; Özata DM; Lu M; Höög A; Bäckdahl M; Larsson C; Lui WO; Zedenius J
    Eur J Endocrinol; 2014 Apr; 170(4):583-91. PubMed ID: 24446485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
    Fernandez-Ranvier GG; Weng J; Yeh RF; Khanafshar E; Suh I; Barker C; Duh QY; Clark OH; Kebebew E
    Arch Surg; 2008 Sep; 143(9):841-6; discussion 846. PubMed ID: 18794420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
    Blanes A; Diaz-Cano SJ
    Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors.
    Almeida MQ; Fragoso MC; Lotfi CF; Santos MG; Nishi MY; Costa MH; Lerario AM; Maciel CC; Mattos GE; Jorge AA; Mendonca BB; Latronico AC
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3524-31. PubMed ID: 18611974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors.
    Doghman M; Arhatte M; Thibout H; Rodrigues G; De Moura J; Grosso S; West AN; Laurent M; Mas JC; Bongain A; Zambetti GP; Figueiredo BC; Auberger P; Martinerie C; Lalli E
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3253-60. PubMed ID: 17566092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.